STOCKWATCH
·
Biotechnology: Pharmaceutical Preparations
Quarterly UpdatesApr 17, 2026, 06:01 AM

Immuron Q3 Global Sales Up 16% to AUD$1.5M

AI Summary

Immuron Limited announced continued unaudited sales growth for Travelan® in Q3 FY26. Global Q3 sales reached AUD$1.5 million, marking a 16% increase year-over-year, with year-to-date sales up 7% to AUD$5.7 million. Australia and Canada showed strong growth, with Canadian Q3 sales more than doubling on pcp and increasing 82% quarter-over-quarter due to new listings and promotions. US sales saw a modest 1% increase, partially offset by the strengthening Australian dollar.

Key Highlights

  • Global Q3 sales AUD$1.5 million, up 16% on prior comparative period (pcp).
  • YTD Mar 2026 global sales AUD$5.7 million, up 7% on pcp.
  • Australia Q3 sales AUD$0.9 million, up 15% on pcp.
  • Canada Q3 sales AUD$0.1 million, up >100% on pcp and 82% on prior quarter.
  • USA Q3 sales AUD$0.5 million, up 1% on pcp.
IMRN
Biotechnology: Pharmaceutical Preparations
Immuron Ltd

Price Impact